

# Vocal Tract Abnormalities in Patients with Two Genodermatoses: Lipoid Proteinosis and Neurofibromatosis Type 1

Original  
Article

*Hossam Mohamed El Dessouky<sup>1</sup>, Dalia Mostafa Osman<sup>2</sup>, Mohamed Islam Gadelhak<sup>3</sup>, Mennat Mehrez<sup>4</sup>, Hanan Afifi<sup>5</sup>, Ghada Yousef El-Kamah<sup>6</sup>, Ayatallah Raouf Sheikhy<sup>7</sup>*

*Department of <sup>1,2,7</sup>Phoniatrics, Faculty of Medicine, Cairo University, <sup>3,5,6</sup>Department of Clinical Genetics, <sup>4</sup>Oro-dental Genetics, Human Genetics and Genome Research Institute, National Research Center, Egypt*

## ABSTRACT

**Objectives:** We aimed to investigate the abnormalities of the oral cavity, pharynx, and larynx of patients with two Genodermatoses: lipoid proteinosis (LP) and Neurofibromatosis type 1 (NF1)

**Study Design:** Cross-sectional study.

**Patients and Methods:** Twenty-five patients with genodermatoses were recruited from the Genodermatoses clinic, NRC, eighteen cases with NF1 and seven cases with LP, where precise cutaneous and oro-dental examinations were done for all patients followed by Naso-pharyngo-laryngeoscopic examination done in the phoniatric unit, faculty of medicine, Cairo university.

**Results:** Oral, pharyngeal, and laryngeal abnormalities were detected in twenty-three, twenty, and seventeen patients respectively. Malocclusion was the main oro-dental abnormality in patients with NF1, while in patients with LP lingual and labial abnormalities were the most common oro-dental abnormalities. Reddish and white-yellowish oropharyngeal swellings were the chief pharyngeal abnormality in patients with NF1 and LP respectively. Congested and thick hypertrophic laryngeal structures are the main laryngeal abnormalities in patients with NF1 and LP respectively. Vocal fold paralysis is not uncommon finding in patients with NF1.

**Conclusion:** Oral, pharyngeal, and laryngeal abnormalities are very common in NF1 and LP. Precise Oro-dental examination and Naso-pharyngo-laryngeoscopic evaluation are recommended for all patients with genodermatoses, especially NF1 and LP. Periodic follow-up by a multidisciplinary team is essential to detect any newly developed lesions or changes in current detected lesions.

**Key Words:** Cutaneous manifestations, laryngeal abnormalities, lipoid proteinosis, neurofibromatosis type1, Oral abnormalities, pharyngeal abnormalities.

**Received:** 19 July 2023, **Accepted:** 10 August 2023

**Corresponding Author:** Mohamed Islam Gadelhak, MD, Department of Clinical Genetics, Human Genetics and Genome Research Institute, National Research Center. **Tel.:** 01023588388, **E-mail:** dr.mohamed\_gadelhaq@yahoo.com

**ISSN:** 2090-0740, 2023

## INTRODUCTION

Genodermatoses refers to a group of genetic disorders that affect the structure and/or function of the skin. They are characterized by an association between cutaneous and extracutaneous abnormalities<sup>[1,2]</sup> commonly including vocal tract abnormalities which may develop at any age causing difficult breathing, feeding, or/and vocalization. Early identification, treatment, and proper follow-up of vocal tract abnormalities particularly those carrying a risk of malignant transformation is critical in management decisions.<sup>[3,4]</sup>

The vocal tract is a container of air extending from the lips, traveling down through the pharyngeal cavity, and terminating at the laryngeal cavity.<sup>[5]</sup> The oral cavity

performs variable functions essential for life, including speech, respiration, mastication, taste, digestion, and swallowing.<sup>[6,7]</sup>

The pharynx is divided into the nasopharynx, the oropharynx, and the hypopharynx or the laryngopharynx, it is considered as a junction to five tubular pathways: It communicates with the nasal cavity through the choanae, the middle ear through the pharyngotympanic tube, the oral cavity through the oropharyngeal isthmus, the larynx through the laryngeal inlet, and the esophagus through the mouth of the esophagus.<sup>[8]</sup>

The larynx is a complex neuromuscular structure that extends from the tip of the epiglottis down to the inferior border of the cricoid cartilage i.e., the entrance of the

trachea, where it continues into the trachea. The larynx can be divided into the supra glottis, the glottis, and the subglottis.<sup>[9,10]</sup>

Among the genodermatoses reported to affect the vocal tract; are Neurofibromatosis type1 (NF1) and Lipoid proteinosis (LP). NF1 is a fully penetrant autosomal dominant (AD) genodermatoses with up to 50% incidence of de novo mutations, it has a prevalence of 1/ 4000 and incidence that varies between 1/2558 and 1/3333 live births independent from ethnicity, race, and gender.<sup>[11]</sup> NF1 is caused by mutations in the tumor suppressor gene neurofibromin located in the long arm of chromosome 17 (17q11.2) resulting in reduced levels of neurofibromin, a cytoplasmic protein involved in controlling the cell cycle and acting as a negative regulator of the cell growth.<sup>[12]</sup>

NF1 affects multiple systems presenting mostly with cutaneous, and neurologic manifestations as major features that might lead to significant morbidity or mortality<sup>[11]</sup>. It is characterized by marked variable expressivity, even within the same family, ranging from very mild to severe life-threatening phenotype making anticipatory guidance difficult.<sup>[13,14]</sup>

LP is a rare multisystem genodermatoses with approximately 400 cases reported in the literature with no gender or ethnic preference.<sup>[15,16]</sup> LP is inherited as an autosomal recessive (AR) disorder, occurring more frequently in countries with higher rates of consanguineous marriages.<sup>[17]</sup> However, few studies proposed that LP may occur due to sporadic mutations.<sup>[18]</sup>

LP is caused by loss of function mutations in the extracellular matrix protein 1 (ECM1) gene located on the long arm of chromosome 1 (1q21.2) involved in maintaining the structural integrity of the skin.<sup>[19,20]</sup> Mutation in the ECM1 gene leads to infiltration of amorphous hyaline-like material in the skin and mucous membrane with underproduction of pro-collagen type I which impairs tissue healing resulting in atrophic scars and overproduction of some structural proteins of the basement membrane causing nodular lesions.<sup>[19,17]</sup>

The purpose of this study is to detect and describe the vocal tract anomalies within NF1 and LP patients to help with early detection and proper management.

#### **PATIENTS AND METHODS:**

---

This cross-sectional study included twenty-five patients (18 NF1 and 7 LP) recruited from the Genodermatoses

clinic, National Research Centre, Egypt. All patients were presented with skin lesions with or without dysphonia. After obtaining informed written consent following thorough explanation according to the Helsinki Declaration of 1975, as revised in 1983, all included patients were evaluated thoroughly:

#### **Clinical evaluation.**

- Detailed medical history recording including three generations pedigree analyses, demographic data, history of present illness, and disease progression.

- Thorough clinical examination with emphasis on: dermatological status, and neurologic affection.

- Imaging studies mainly brain neuroimaging, as well as ophthalmological and auditory evaluation studies, were recorded.

- Patients were diagnosed based on each disease's cardinal diagnostic manifestations:

In cases of NF1, patients were diagnosed based on the presence of at least two of the diagnostic clinical features stated by the National Institutes of Health (NIH) (Table 1).<sup>[14]</sup>

For LP patients, acneiform scarring and the hyperkeratotic verrucous lesions were described in detail.

- Complete Oro-dental examination was carried out next with a full description of any abnormalities affecting the lips, dentition, alveolus, buccal mucosa, floor of the mouth, tongue, soft palate, and/or hard palate.

- Laryngeoscopic evaluation: All patients were examined using a flexible fiberoptic laryngoscope. The following structures were examined, and photo documented: nasopharynx, valleculae, epiglottis, vocal folds, pyriform fossae, arytenoids, inter-arytenoids region, anterior commissure, ventricular folds (VFs), aryepiglottic folds, and post-cricoid region. The items to be noticed were the mucous membrane, vocal folds configuration, vocal folds gross mobility (adduction and abduction), loss of tissue or atrophy, symmetry of the glottis, ventricular bands girth, and position on phonation and glottic closure.

**Table 1:** National Institutes of Health (NIH) diagnostic criteria of NF1

---

Six or more café-au-lait macules (CALMS)
Axillary freckling or freckling in inguinal regions
Two or more neurofibromas of any type or one or more plexiform neurofibromas
Two or more Lisch nodules
Bone lesion with sphenoid bone dysplasia or thickening of the cortex of the long bones with or without pseudoarthrosis
An optic pathway glioma
A first-degree relative with neurofibromatosis type 1 diagnosed by the above criteria

---

**RESULTS:****I. Clinical results:**

The twenty-five studied patients included 6 males and 19 females whose ages ranged from 15 months - 39 years. Pedigree analyses revealed positive consanguinity in 100% of LP pedigrees and in only 27.8% of NF1 also similarly affected family members were detected in 83% of NF1 and 57% of the LP pedigrees (Table 2). All included patients were diagnosed clinically based on their different characteristic cutaneous manifestations (Fig. 1) which were the main complaint in all patients (Table 3) coupled with dysphonia in all cases of LP patients and with a history of at-birth surgical excision of laryngeal neurofibroma in one NF1 patient who suffered from difficult breathing.

The different dermatological manifestations are presented in (Table 4) where café au lait macules (CALMs) were the predominant skin lesion in all NF1 patients (n=18), followed by freckles in 10/18 then neurofibromas in 7/18 cases, while the facial acneiform scarring and the hyperkeratotic verrucous lesions were the chief skin lesions presenting in all patients with LP (7/7) followed by moniliform blepharosis in 4/7 and waxy deposits in 2/7 cases.

**II. Oral abnormalities were evident in 23 patients:**

**II.a. NF1 patients:** Dental malocclusion was the most common oral abnormality in patients with NF1 affecting 15/18 patients from which 2 patients had also dental hypo-calcification. Fissured tongue with abnormal coating comes next affecting 6/18 patients one of them had a painless ulcer on the dorsum of the tongue and another had macroglossia. Two patients had fissured thick lips, one had a thick upper labial frenulum. Three patients had racial gingival and mucosal pigmentation and two had high arched palate. One patient had plexiform neurofibroma arising from the floor of the mouth giving the impression of a second tongue.

**II.b. LP Patients:** Stiff tongue with limited protrusion and thick fissured lips were the most common oral abnormality; presented in all patients (n=7) with thick lingual frenulum in 5 patients. Oral mucosa was firm in

5 patients with whitish deposits. Three patients had long uvula, two patients had broad uvulae, and one patient had whitish depositions on the palate and oral surface of the uvula. The gingiva was the least affected area; showing hypertrophy in one patient.

**III. Pharyngeal abnormalities were evident in 20 patients:**

Oropharynx was the most affected region (n=20), hypopharynx (n=13), and nasopharynx (n=1). Both oral and pharyngeal detected abnormalities within our cohort are presented in (Table 6 and Fig. 2 & 3).

**III.a. NF1 patients:** multiple reddish nodular swellings were the main finding affecting mainly the oropharynx (n=13) while the nasopharynx showed no abnormalities. A relatively large pulsatile mass in the right side of the posterior oropharyngeal wall was detected in one NF1 patient.

**III.1.b. LP patients:** whitish yellowish deposits were the chief predominant pharyngeal finding affecting the oropharynx in all patients (n=7), hypopharynx (n=6), and nasopharynx (n=1). Whitish deposition in the inlet of the esophagus was noticed in one patient.

**IV. Laryngeal abnormalities were evident in 17 patients:**

Detected laryngeal abnormalities are documented in (Table 7 and Fig. 4).

**IV.a. NF1 patients:** mucosal congestion was the main abnormality found in the larynx affecting arytenoids (n=9), intra arytenoid region (n=3) and aryepiglottic folds (n=2). In four NF1 patients vocal fold abnormalities were detected in the form of; bilateral symmetrical swelling in the middle of the membranous part of the vocal folds (n=2), unilateral vocal fold paralysis after surgical excision of laryngeal plexiform neurofibroma (n=1) and unilateral vocal fold paralysis accidentally discovered during this study (n=1).

**IV.b. LP patients:** Hypertrophic thick mucosa was the predominant laryngeal finding detected in vocal folds, arytenoid, and intra-arytenoids (n=7), aryepiglottic fold

(n=5), and ventricular folds (n=2). Two patients had whitish deposition in the arytenoids and intra-arytenoid area. One patient had bilateral asymmetrical vocal fold whitish deposits.

Only one patient in this study shows no abnormalities in the oral cavity or pharynx nor larynx. The percentage of affection for the oral cavity, pharynx, and larynx among the patients in this study are summarized in (Tables 5 and 6).

**Table 2:** Basic Demographic data

	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Gender		
Men	2 (11.1)	4 (57.1)
Women	16 (88.9)	3 (42.9)
Consanguinity		
Yes	5 (27.8)	7 (100)
No	13 (72.2)	0
Similarly affected family members		
Yes	15 (83.3)	4 (57.1)
No	3 (16.7)	3 (42.9)

**Table 3:** Main complain upon presentation

	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Skin lesions		
Since birth	13 (72.2)	4 (57.1)
Childhood	4 (22.2)	3 (42.9)
Adulthood	1 (5.6)	0
Dysphonia		
Since birth	0	6 (85.8)
Childhood	0	1 (14.2)
Adulthood	0	0

**Table 4:** The type of the skin lesions

	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Café au lait Macules	18 (100)	0
Freckles	10 (55.6)	0
Neurofibromas	7 (38.9)	0
Acneiform scarring	0	7 (100)
hyperkeratotic lesions	0	7 (100)
Moniliform blepharosis	0	4 (57.1)
Waxy deposits	0	2 (28.6)

**Table 5:** Percentage of affection of the oral cavity, pharynx and the larynx

	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Oral cavity	16 (88.9)	7 (100)
Pharynx	13 (72.2)	7 (100)
Larynx	10 (55.5)	7 (100)

**Table 6:** Oral and Pharyngeal abnormalities

	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Oral abnormalities		
Dental	5 (83.3)	5 (71.4)
Lingual	6 (33.3)	7 (100)
Labial	3 (16.7)	7 (100)
Mucosa	3 (16.7)	5 (71.4)
Gingival	3 (16.7)	1 (14.3)
Palatal	2 (11.1)	6 (85.7)
Pharyngeal abnormalities		
Nasopharynx	0	1 (14.3)
Oropharynx	3 (72)	7 (100)
Hypopharynx	7 (38.9)	6 (85.7)

**Table 7:** Laryngeal abnormalities


	Patients, n (%)	
	NF1 (n=18)	LP (N=7)
Vocal folds	4 (22.2)	7 (100)
Arytenoids	9 (50)	7 (100)
Intra-arytenoid area	3 (16.7)	7 (100)
Aryepiglottic folds	2 (11.1)	5 (71.4)
Ventricular folds	0	2 (28.6)




**Fig. 1:** Cutaneous manifestations: In patients with NF1 (A-C): A: CALMs - B: Freckles – C: Neurofibromas. In patients with LP (D-G): D: Facial Acneiform scarring – E: Moniliform blepharosis. F: Waxy deposits. G: hyperkeratotic verrucous lesions



**Fig. 2:** Oral abnormalities: In patients with NF1 (A-C): A: Dental malocclusion B: Neurofibroma of the tongue base. C: Thick fissured lips. In patients with LP (D-G): D: Stiff tongue. E: Whitish deposition on the dorsum of the tongue. F: Thick firm lingual frenulum. G: Whitish deposition on the palate and uvula.



**Fig. 3:** Pharyngeal abnormalities: (A): Multiple reddish nodular swellings in patient with NF1. (B): Multiple yellowish white swellings in patient with LP.



**Fig. 4:** Laryngeal abnormalities: In patients with NF1 (A-b): A: Congested arytenoids and intra-arytenoid area and bilateral symmetrical vocal fold masses. B: Forward tilting of the left arytenoid. In patients with LP (C-D) C: Thick hypertrophic glottic and supraglottic region. D: Whitish deposition in the arytenoid and intra arytenoid area.

## DISCUSSION

Genodermatoses are a heterogeneous group of rare genetic disorders with dermatological diagnostic clues, that are characterized by association between cutaneous and extracutaneous abnormalities. Thorough phenotypic analyses of rare disorders could provide clues to diagnostic as well as managerial procedures. Studying abnormalities in the oral cavity, pharynx, and larynx among genodermatoses patients could be critical for accurate diagnosis and proper management of several of these disorders.<sup>[21]</sup>

The current study included 25 cases; eighteen NF1 patients with NF1 presented to the Genodermatoses Clinic, NRC complaining of Café au lait macules (CALMs) which is the earliest cutaneous manifestation of NF1.<sup>[13]</sup>

The other seven patients were presented with dysphonia coupled with skin lesions. Dysphonia is the first and most striking manifestation in LP patients presenting usually at birth or infancy followed by skin scarring.<sup>[19,22,23]</sup> Contrary to previous reports, one of our cohort of LP patients developed skin lesions since birth followed by dysphonia during childhood however, in their report, Srinivas *et al.*, described a similar presentation in one of their six studied LP cases.<sup>[24]</sup>

Gingiva is considered part of the dermatological examination and accordingly, oral manifestations are common clinical features in genodermatoses, they are detected in up to 92% of NF1 patients following the detection of cutaneous manifestations.<sup>[21]</sup> Santoro *et al.* & Aşkın *et al.* reported the tongue as the primary site to be affected in patients with NF1.<sup>[12,21]</sup> Sixteen of our NF1 cohort had oral abnormalities however, lingual abnormalities were the second most common type following dental malocclusion. Mucosal and gingival pigmentations which are also considered among common clinical features in NF1 cases were detected in 3/18 of our NF1 patients.<sup>[14,25]</sup> Plexiform neurofibroma arising from the floor of the mouth giving the impression of a second tongue was detected in one NF1 patient. Plexiform neurofibroma is a very rare finding inside the oral cavity, apparently originating from the fifth cranial nerve and its branches.<sup>[26,27,14]</sup> A close follow-up is mandatory for this oral neurofibroma to detect any symptomatic growth or malignant transformation and accordingly provide proper intervention when needed.

Oral manifestations are also considered as predominant clinical feature in patients with LP. Thick-fissured lips and stiff tongue with limited protrusion were the chief predominant complaints as well as thick

lingual frenulum noticed in five/seven of LP studied patients. In the current study, tongue and lingual frenulum abnormalities were notably high: 100% and 71.4% compared to 55.6% and 48.1%, respectively, reported in a systemic literature review of eighty-one LP patients in Middle East and North Africa.<sup>[20]</sup> That review included only one Egyptian LP patient which may point to possible higher prevalence of those clinical features within the Egyptian population. This is an important clinical finding particularly for the phoneticians and dentists who may be the first physicians to encounter LP patients for early identification.

Laryngeal examination revealed multiple reddish nodular pharyngeal swellings affecting mainly the oropharynx in thirteen of the studied NF1 patients which are mostly lymphatic inflammatory reactions. An unclear link between neurofibromas and the inflammatory environment that is critical for its development and progression was suggested in some studies.<sup>[28, 29]</sup> In one of the studied NF1 patients, a relatively large pulsatile mass was detected on the right side of the posterior oro-pharyngeal wall for which a CT scan was requested. Both aberrant course of ICA and cervical ICA aneurysm could be a life-threatening explanation for this endoscopic finding.<sup>[30,31]</sup>

Pharyngeal whitish-yellowish deposits were endoscopically noted in all LP patients involved in this study which are considered a constant finding in LP.<sup>[32, 22,19]</sup> Whitish deposition on the esophageal inlet, was detected in one of our studied LP patients. Multiple yellowish nodules throughout the esophagus were detected in an upper GIT endoscopy for a Brazilian patient. This was considered a very rare clinical finding in LP.<sup>33</sup> In 2017, one LP patient was diagnosed with absent esophageal peristalsis which was explained by infiltration of hyaline materials in the muscular layer of the esophagus, although histological examination was not done to confirm this explanation.<sup>[34]</sup> Upper GIT endoscopy may be of beneficial value in patients with LP particularly those complaining of dysphagia.

Congested laryngeal structure, mainly the arytenoids, was significantly noticed in our cohort of NF1 patients, and congested gastrointestinal tract mucosa was reported in NF1 patients in different studies.<sup>[35,36]</sup> Also, two patients had bilateral symmetrical vocal fold swelling between the anterior third and posterior two third of the vocal folds. These bilateral vocal fold swellings are most probably vocal fold nodules (VFNs). VFNs are bilateral benign growths of variable size found at the midpart of the membranous vocal cords at the junction between the anterior and middle third of the vocal folds that develop

secondary to repetitive mucosal injury due to laryngeal hyperfunction and vocal abuse.<sup>[37]</sup> Neurofibroma arising from the glottis is a very rare finding and is usually unilateral.<sup>[38]</sup>

In the current study, one patient had a history of laryngeal neurofibroma since birth that originated from the right aryepiglottic fold causing respiratory obstruction, necessitating surgical excision that was complicated by unilateral vocal fold paralysis. The aryepiglottic folds are considered the most common laryngeal site to be affected by neurofibromas followed by the arytenoids due to the rich nerve supply by the superior laryngeal nerve and its anastomosis with recurrent laryngeal nerve.<sup>[39]</sup> Unilateral vocal fold paralysis was also detected in another NF1 patient in our cohort. Vocal fold paralysis due to neurofibroma -either in the larynx or elsewhere- was found to be a more common fibro-endoscopic finding than laryngeal neurofibromas in NF1 patients.<sup>[40,41,42]</sup>

Among our studied LP patients, thick hypertrophic laryngeal structure was the main detected laryngoscopic finding. Arytenoids, intra-arytenoid area, and the vocal folds were the main affected regions. Yukkaldiran *et al.* considered thickening, and hypertrophy of laryngeal structure a constant clinical finding in LP patients.<sup>[43]</sup> Two patients had whitish depositions on the arytenoids and intra-arytenoid area and one patient had similar depositions on vocal folds. Whitish deposition in the larynx of LP patients was reported in different studies before.<sup>[19,32]</sup>

## CONCLUSION

---

In conclusion, phenotypic variability and several rare findings were detected among studied patients as well as common abnormalities in the oral cavity, pharynx, or larynx in patients with Genodermatoses. Precise Oro-dental examination and Flexible Naso-pharyngo-laryngeoscopic evaluation are recommended for all genodermatoses patients to reach an early precise diagnosis. Periodic follow-up by a multidisciplinary team is essential to detect any newly developed lesions or changes in current detected lesions for early prevention and proper management.

## CONFLICT OF INTEREST

---

There are no conflicts of interest.

## REFERENCES

---

1. Cheraghlou S, Lim Y, Choate KA. Mosaicism in genodermatoses. *Clin Dermatol.* 2020;38(4):408-420. doi:10.1016/j.clindermatol.2020.03.008

2. Parker JC, Rangu S, Grand KL, Bhoj EJ, Castelo-Soccio L, Sheppard SE. Genetic skin disorders: The value of a multidisciplinary clinic. *Am J Med Genet Part A*. 2021;185(4):1159-1167. doi:10.1002/ajmg.a.62095
3. Ko CJ, Atzmony L, Lim Y, *et al.* Review of genodermatoses with characteristic histopathology and potential diagnostic delay. *J Cutan Pathol*. 2019;46(10):756-765. doi:10.1111/cup.13520
4. Bhateja S, Sachdeva A, Arora G. Oral genodermatoses. *J Educ Technol Heal Sci*. 2020;6(3):62-65. doi:10.18231/j.jeths.2019.016
5. Fitch WT; Giedd J. Morphology and development of the human vocal tract: A study using magnetic resonance imaging. *The Journal of the Acoustical Society of America*. 1999; 106(3), 1511–. doi:10.1121/1.427148
6. Bruch JM, Treister NS. *Clinical Oral Medicine and Pathology*. Humana Press; 2010.
7. Von Arx T, Lozanoff S. *Clinical oral anatomy*. Springer;2017.
8. Fatima H. Oropharyngeal Findings at Upper Endoscopy. *Clin Gastroenterol Hepatol*. 2019;17(12):2423-2428. doi:10.1016/j.cgh.2019.05.038
9. Merati AL, Rieder AA. Normal endoscopic anatomy of the pharynx and larynx. *Am J Med*. 2003;115(3 SUPPL. 1):10-14. doi:10.1016/S0002-9343(03)00187-6
10. Piazza C, Ribeiro JC, Bernal-Sprekelsen M, Paiva A, Peretti G. Anatomy and physiology of the larynx and hypopharynx. In: Anniko M, Bernal-Sprekelsen M, Bonkowsky V, Bradley PJ, Iurato S (Eds.) *Otorhinolaryngology, Head and Neck Surgery*. Berlin, Heidelberg: Springer Nature, str; 2010:461-471
11. Bergqvist C, Servy A, Valeyrie-allanore L, *et al.* Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. 2020;3:1-23.
12. Santoro R, Santoro C, Loffredo F, *et al.* Oral clinical manifestations of neurofibromatosis type 1 in children and adolescents. *Appl Sci*. 2020;10(14):1-9. doi:10.3390/app10144687
13. Wilson BN, John AM, Handler MZ, Schwartz RA. Neurofibromatosis type 1: New developments in genetics and treatment. *J Am Acad Dermatol*. 2021;84(6):1667-1676. doi:10.1016/j.jaad.2020.07.105
14. Cherifi H, Fournier B, Berdal A, McAlpin B, Sitbon I-Y, Gogly B. Oral Manifestations of Neurofibromatosis Type 1. *J Cosmet Dermatological Sci Appl*. 2019;09(01):41-55. doi:10.4236/jcdsa.2019.91004
15. Afifi HH, Amr KS, Tosson AMS, Hassan TA, Mehrez MI, El-Kamah GY. Lipoid proteinosis: A clinical and molecular study in Egyptian patients. *Gene*. 2017;628:308-314. doi:10.1016/j.gene.2017.07.026
16. Agredano PM, del Barrio CM, Martinez MC, Cabrera CA. Intracranial calcifications associated with epilepsy: A case report of lipoid proteinosis. *Seizure*. 2020;83(November):172-174. doi:10.1016/j.seizure.2020.10.027
17. Lourenço AG, Araújo VC, Passador-Santos F, Sperandio M, Neville BW, Dorta RG. Lipoid proteinosis: A rare disease in pediatric dentistry. *Braz Dent J*. 2020;31(2):186-189. doi:10.1590/0103-6440202003054
18. Frenkel B, Vered M, Taicher S, Yarom N. Lipoid proteinosis unveiled by oral mucosal lesions: a comprehensive analysis of 137 cases. *Clin Oral Investig*. 2017;21(7):2245-2251. doi:10.1007/s00784-016-2017-7
19. Vishwanath T, Dhurat R, Borawake S, Joshi A, Agrawal S, Ghate S. Utility of acitretin in improving quality of life in lipoid proteinosis. *Ann Indian Acad Otorhinolaryngol Head Neck Surg*. 2019;3(1):49. doi:10.4103/aiao.aiao\_4\_19
20. Alraddadi M. Case Report Lipoid proteinosis in Middle East and North Africa : A case report and literature review. 2019;8(1):95-100. doi:10.5455/ijmsph.2019.09117612102018
21. Aşkın Ö, Engin B, Gencebay G, Tüzün Y. A multistep approach to the diagnosis of rare genodermatoses. *Clin Dermatol*. 2020;38(4):399-407. doi:10.1016/j.clindermatol.2020.03.009
22. Sharma A, Gupta L, Balai M, Khare A. Lipoid proteinosis: A series of three cases. *Indian J Paediatr Dermatology*. 2017;0(0):0. doi:10.4103/ijpd.ijpd\_131\_16
23. Natarajan B, Prathap P, Asokan N, Balakrishnan S. Lipoid proteinosis – An erratic disease with an archetypal presentation. *J Ski Sex Transm Dis*. 2020;2(1):56-58. doi:10.25259/jsstd\_9\_2020

24. Srinivas S, Maganthi M, Chandrasekaran P, Gowdra A, Palany R. Clinical and molecular characterization of lipoid proteinosis in three Indian families. *Indian J Paediatr Dermatology*. 2020;21(3):167. doi:10.4103/ijpd.ijpd\_9\_20
25. Serra G, Antona V, Corsello G, Zara F, Piro E. NF1 microdeletion syndrome : case report of two new patients. Published online 2019:1-7.
26. Visnapuu V, Peltonen S, Alivuotila L, Happonen RP, Peltonen J. Craniofacial and oral alterations in patients with Neurofibromatosis 1. *Orphanet J Rare Dis*. 2018;13(1):1-9. doi:10.1186/s13023-018-0881-8
27. Broly E, Lefevre B, Zachar D, Hafian H. Solitary neurofibroma of the floor of the mouth: Rare localization at lingual nerve with intraoral excision. *BMC Oral Health*. 2019;19(1):1-8. doi:10.1186/s12903-019-0888-0
28. Karmakar S, Reilly KM. The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. *CNS Oncol*. 2017;6(1):45-60. doi:10.2217/cns-2016-0024
29. Choi K, Komurov K, Fletcher JS, *et al*. An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. *Sci Rep*. 2017;7(January):1-14. doi:10.1038/srep43315
30. Moratti C, Anderson T. Giant extracranial aneurysm of the internal carotid artery in neurofibromatosis type 1: A case report and review of the literature. *Interv Neuroradiol*. 2012;18(3):341-347. doi:10.1177/159101991201800315
31. Singh A, Kairo AK. Aberrant internal carotid artery presenting as oropharyngeal mass. *Eurasian Clin Anal Med*. 2019;07(01). doi:10.4328/aemed.147
32. Oz F, Kalekoğlu N, Karakullukçu B, Oztürk O, Oz B. Lipoid proteinosis of the larynx. *J Laryngol Otol*. 2002;116(9):736-739. doi:10.1258/002221502760238082
33. Lima JC, Nagasako CK, Montes CG, *et al*. Case Report Gastrointestinal Involvement in Lipoid Proteinosis : A Ten-Year Follow-Up of a Brazilian Female Patient. 2014;2014:8-11. doi:10.1155/2014/952038
34. Afshar B, Sadeghi A, Amani M, Ali Asgari A. Esophageal Aperistalsis in a Patient with Lipoid Proteinosis. *Middle East J Dig Dis*. 2018;10(1):55-58. doi:10.15171/mejdd.2017.92
35. Adams W, Mitchell L, Candelaria-Santiago R, Hefner J, Gramling J. Concurrent ulcerative colitis and neurofibromatosis type 1: The question of a common pathway. *Pediatrics*. 2016;137(2). doi:10.1542/peds.2015-0973
36. Ravegnini G, Quero G, Sammarini G, *et al*. Correction to: Gastrointestinal juvenile-like (inflammatory/hyperplastic) mucosal polyps in neurofibromatosis type 1 with no concurrent genetic or clinical evidence of other syndromes (*Virchows Archiv*, (2019), 474, 2, (259-264), 10.1007/s00428-018-2462-6). *Virchows Arch*. 2019;474(2):265. doi:10.1007/s00428-018-2472-4
37. Baraka M, El-Dessouky H, Behiry EA, Ezzat E, ... Role of steroids injection in treatment of minimal associated pathological lesions. *Menoufia Med ...*. Published online 2020:333-338. doi:10.4103/mmj.mmj
38. Liu J, Wong CF, Lim F, Kanagalingam J. Glottic neurofibroma in an elderly patient: A case report. *J Voice*. 2013;27(5):644-646. doi:10.1016/j.jvoice.2013.02.002
39. Mahmood A. Solitary True Vocal Cord Neurofibroma: An Unexpected Pathology. *Med J Clin Trials Case Stud*. 2020;4(1). doi:10.23880/mjccs-16000246
40. Naunheim MR, Plotkin SR, Franco RA, Song PC. Laryngeal manifestations of neurofibromatosis. *Otolaryngol - Head Neck Surg (United States)*. 2016;154(3):494-497. doi:10.1177/0194599815626133
41. Rajasekharan C, Thomas V, Parvathy R, Meera R. Neurofibromatosis type 1 (NF1) with vocal cord palsy: Baffling presentation of a benign tumour. *BMJ Case Rep*. 2013;1:2-4. doi:10.1136/bcr-2013-009202
42. Choi SW, Kim WJ. Vocal Cord and Diaphragmatic Paralysis in a Patient With Bilateral Mediastinal Neurofibromatosis Type 1. *Ear, Nose Throat J*. 2021;100(10):1010S-1011S. doi:10.1177/0145561320933959
43. Yukkaldiran A, Aksoy M, Yesilova Y, *et al*. The frequency of laryngeal involvement in lipoid proteinosis patients. *Ann Med Res*. 2019;(0):1. doi:10.5455/annalsmedres.2019.01.059